AI Pilots and Strategic Partnerships: ExM Leaders Basel 2026 Report
EXCLUSIVE DOWNLOAD AI Pilots and Strategic Partnerships Download this report from External Manufacturing Leaders Basel 2026 edition for candid insights into where AI is earning
Just-Evotec Biologics Initiates Phase 1 Trial of $123.9M Orthopoxvirus Antibody Program
Evotec SE has initiated a Phase 1 clinical trial evaluating JST-018, an investigational cocktail of monoclonal antibodies targeting orthopoxviruses. The program was developed by Evotec’s
How ExoZymes Is Running a 10-CDMO RFP for CDMO Selection
“We can adjust and be flexible around equipment configuration, but we can’t be flexible around what is a clear communicator and an honest partner.” Damien
Rose BioSolutions Appoints David Enloe as CEO
Rose BioSolutions has appointed David Enloe as Chief Executive Officer, adding an executive with more than 35 years of experience in biotech and pharmaceutical services.
Scinai Immunotherapeutics Ends PC111 License Deal, Refocuses on NanoAb Platform
Scinai Immunotherapeutics Ltd. has ended its option and license arrangements with PinCell S.r.l. relating to PC111 and will refocus its R&D resources on its NanoAb
Gilead Sciences Opens 182,000-Square-Foot Research Center in California
Gilead Sciences, Inc. has opened its 182,000-square-foot Research Center at its headquarters in Foster City, California, expanding the company’s research capabilities in oncology, inflammation and
Charles River Laboratories Expands Endotoxin Cartridge Capacity With Automated Suite
Charles River Laboratories International, Inc. has reached full operational capacity of its Endosafe® Cartridge Technology Automated Manufacturing Suite, expanding bacterial endotoxin testing cartridge production while
HOVIONE Names Stefan Doboczky as CEO
HOVIONE HOLDING AG has appointed Stefan Doboczky as Chief Executive Officer, effective April 1, 2027. Doboczky has served as Chairman of the company’s Board of
CNS Drug Development Enters a New, More Evidence-Driven Era
Central nervous system (CNS) drug development has long been considered one of the toughest corners of the pharma industry, but a panel at NLSDays 2026
Global Biopharma Financing Hit a 4-Year High in Q4 2025, Fueled by $200bn in Pharma M&A
Global biopharma financing closed out 2025 on its strongest footing in years: Q4 was among the strongest quarters for financing in over four years, with
